DRUG · Mapped RxNorm record
Ibalizumab
Normalized identity: ibalizumabView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1
NCT00784147
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Ibalizumab
Normalized identity: ibalizumabView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedDose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
HIVunresolved
Interventions
IbalizumabDRUG · verified · RxNorm: ibalizumab
IbalizumabDRUG · verified · RxNorm: ibalizumab
Sponsors & collaborators
TaiMed Biologics Inc.lead sponsor
Mapped research locations
HoustonTexas, United States5San FranciscoCalifornia, United States2DenverColorado, United States2San JuanPuerto Rico2New YorkNew York, United States1ChicagoIllinois, United States1Los AngelesCalifornia, United States1DallasTexas, United States1MiamiFlorida, United States1PortlandOregon, United States1Washington D.C.District of Columbia, United States1IndianapolisIndiana, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00784147 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.